A Phase 3 Randomized Non Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
- Sponsor:
- COG
- Sponsor Study ID:
- ACNS1833
- CTO #:
- 103506
- NCT Number:
- NCT04166409
- Phase:
- III
- Protocol Type:
- Treatment
- Age Group:
- Children
- Disease Sites:
- Brain and Nervous System
- Study Objectives:
- A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
- eConsent:
- Not available
- Study Documents:
-
Open Study Documents
(MUSC NetID required for document access)
For more information about this trial please contact the study team:
-
Medical University of South Carolina
- Principal Investigator, Kraveka, Jacqueline, at kravekjm@musc.edu .
- Study Coordinator, Helfrey, Lauren, at helfrey@musc.edu .
Trial opened at the following institutions:
Medical University of South Carolina